Clinical Trial Update: The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia [NA]

View source ↗

Summary

A terminated clinical trial evaluating the effect of the lumacaftor/ivacaftor combination on markers of hyperglycemia in cystic fibrosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Diabetes Mellitus

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Cystic Fibrosis, Diabetes | NA | Status: TERMINATED